Skip to content

Gross margin at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
60.7%+3.0pp
Viatris logo
ViatrisVTRS
34.4%-2.5pp
PTH
Pelthos Therapeutics Inc.PTHS
79.6%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
93.4%+3.7pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
86.1%+7.2pp
Opko Health logo
Opko HealthOPK
36%+4.2pp

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.4%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Calculated from Scilex Holding Company’s reported figures.

Based on trailing twelve months.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's gross margin?
Scilex Holding Company (SCLX) reported gross margin of 59.7% in Q1 2026.
How has Scilex Holding Company's gross margin changed year-over-year?
Scilex Holding Company's gross margin decreased by 17.1% year-over-year, from 71.9% to 59.7%.
What is the long-term trend for Scilex Holding Company's gross margin?
Over 5 years (2020 to 2025), Scilex Holding Company's gross margin has grown at a -6.5% compound annual growth rate (CAGR), from 90.9% to 65%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.